好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Remote Smartphone-based Monitoring of Parkinson’s Disease: A Real-world Multicenter Evaluation Across U.K. and U.S. Health Systems
Movement Disorders
S26 - Movement Disorders: Clinical Trials and Therapeutics (1:12 PM-1:24 PM)
002

To evaluate real-world use of a multi-modal digital platform (Kneu Health) for remote monitoring of idiopathic Parkinson’s disease (PD) across UK and US health systems.

PD prevalence is rising, creating substantial morbidity and strained healthcare resources. Challenges include limited capacity for frequent monitoring, objective medication management, and access to care. Scalable, objective tools to assess and aid patient management are needed internationally.

A smartphone based platform was developed to objectively quantify PD signs and symptoms via digital assessments of voice, balance, gait, finger dexterity, reaction time, rest/postural tremor, and cognitive function. The platform was deployed across 11 UK NHS hospitals and 2 US healthcare providers. Use per site ranged from 3-18 months. 726 patients completed smartphone assessments in a real-world setting. Machine learning models were used to estimate scores including MDS-UPDRS, and key metrics were displayed on a clinician dashboard. Use in clinics was evaluated, including clinical utility, efficiency and service impact. An additional 515 PD patients provided paired clinical data to train models.

Over 800,000 digital measures were completed. Smartphone derived motor features correlated with corresponding MDS-UPDRS components (r=0.12 to 0.51, p<0.05) and were sensitive to daily symptom fluctuations. 93% of patients found the technology easy to use and sustained improvements of up to 30% were observed across patient empowerment, confidence, and knowledge. Dashboard data supported medication optimization in 53% of clinical consultations and saved on average 20% consultation time. At the most mature UK site, PD related emergency admissions decreased by 1.2% versus an 8.6% national increase. In the US, 11% of patients reported avoiding an unplanned hospital or emergency visit within 3-6 months of use.

Remote smartphone-based assessments enable clinically actionable longitudinal monitoring of PD in UK and US healthcare settings. The approach was acceptable to patients, improved clinical decision-making, and demonstrated real-world impact on service outcomes.

Authors/Disclosures
Kinan Muhammed, MBBS, PhD, MRCP (Neu Health)
PRESENTER
Dr. Muhammed has received personal compensation for serving as an employee of Kneu Health Limited. Dr. Muhammed has or had stock in Kneu Health.Dr. Muhammed has received intellectual property interests from a discovery or technology relating to health care.
Francis Chmiel No disclosure on file
Ledia Agley, PhD Dr. Agley has nothing to disclose.
krystal Hattar Mrs. Hattar has nothing to disclose.
Michele Tagliati, MD, FAAN (Cedars-Sinai Medical Center) Dr. Tagliati has received publishing royalties from a publication relating to health care.
Bridget Frommel, Master of Arts Ms. Frommel has nothing to disclose.
Cheri Phillips, PA Ms. Phillips has nothing to disclose.
Vikrant Rai, MBBS, PhD Dr. Rai has nothing to disclose.
Diego Rodriguez, Sr., MD No disclosure on file
Olivia Laun Ms. Laun has nothing to disclose.
Jennifer T. Liu, MD (Massachusetts General Hospital) Dr. Liu has nothing to disclose.
Widad Abou Chaar, MD (Brigham and Women's Hospital) Dr. Abou Chaar has nothing to disclose.
Barbara Changizi, MD Dr. Changizi has nothing to disclose.
Daniel N. El Kodsi, PhD Dr. El Kodsi has nothing to disclose.
Vikram Khurana, MD, PhD (Kings County Hospital) Dr. Khurana has received personal compensation for serving as an employee of DaCapo BrainScience. An immediate family member of Dr. Khurana has received personal compensation for serving as an employee of Arbor Therapeutics. Dr. Khurana has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sanofi. Dr. Khurana has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Yoda Pharmaceuticals. Dr. Khurana has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Lundbeck. Dr. Khurana has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for DaCapo Brainscience. Dr. Khurana has received personal compensation in the range of $0-$499 for serving as an officer or member of the Board of Directors for Mission MSA. Dr. Khurana has stock in DaCapo Brainscience. The institution of Dr. Khurana has received research support from Sanofi. The institution of Dr. Khurana has received research support from Janssen. The institution of Dr. Khurana has received research support from Biohaven. The institution of Dr. Khurana has received research support from Tiziana Life Sciences. Dr. Khurana has received intellectual property interests from a discovery or technology relating to health care.
Kristen L. Mason Mrs. Mason has received personal compensation for serving as an employee of Harmony Biosciences.
Andrew J. Graham, MD (Dept of Clinical Neurology) Dr. Graham has received personal compensation in the range of $500-$4,999 for serving as an officer or member of the Board of Directors for Cambridge Dementia Course.
teresa clarke, RN Mrs. clarke has nothing to disclose.
Rachel Rich, RN Ms. Rich has nothing to disclose.
Jeremy Cosgrove, MD, MB ChB (hons) Dr. Cosgrove has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for BIAL.
Stephen Butterworth, MD Dr. Butterworth has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for bial.
Amanda y. Hulejczuk, RN, CNS Mrs. Hulejczuk has nothing to disclose.
Mary E. Burt, RN Mrs. Burt has nothing to disclose.
Rebecca Heslop Mrs. Heslop has nothing to disclose.
Antonella Macerollo Antonella Macerollo has nothing to disclose.
Richard J. Ellis, MBBS (The Walton Centre for Neurology and Neurosurgery) Dr. Ellis has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Merz. Dr. Ellis has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Teva UK. Dr. Ellis has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Britannia Pharmaceuticals.
joanne bromley, RN (Oxford University Hospitals) Mrs. bromley has nothing to disclose.
Nicola F. Findlay, RN Mrs. Findlay has nothing to disclose.
Damian R. Jenkins, MA, MB Bch, MRCP (British Army) Dr. Jenkins has nothing to disclose.
Nagaraja Sarangmat (Oxford University Hospital NHS foundation trust) Nagaraja Sarangmat has nothing to disclose.
Michele Hu, MD The institution of Dr. Hu has received personal compensation in the range of $0-$499 for serving as a Consultant for Lundbeck. The institution of Dr. Hu has received personal compensation in the range of $0-$499 for serving as a Consultant for ESCAPE Bio. The institution of Dr. Hu has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Evidera. The institution of Dr. Hu has received research support from Parkinson's UK. The institution of Dr. Hu has received research support from Oxford BRC.